Myriad Genetics (MYGN) Reports In-Line Q2 EPS, misses on revenue, provides guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.17 -1.86%
Financial Fact:
Total costs and expenses: 171.3M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Financial Fact:
Total costs and expenses: 171.3M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $183.5 million versus the consensus estimate of $187.07 million.
GUIDANCE:
Myriad Genetics sees FY2023 EPS of ($0.36)-($0.24). Myriad Genetics sees FY2023 revenue of $730-750 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Metalla Royalty & Streaming Ltd. (MTA) Reports In-Line Q2 EPS
- Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
